NCT06882356 The Glaucoma and Retinopathy Screening Study
| NCT ID | NCT06882356 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Massachusetts Eye and Ear Infirmary |
| Condition | Glaucoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 2,000 participants |
| Start Date | 2025-07-16 |
| Primary Completion | 2030-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 2,000 participants in total. It began in 2025-07-16 with a primary completion date of 2030-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma. Participants will: Have an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset
Eligibility Criteria
* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system for clinical care at primary care centers. * Individuals who are able and willing to provide informed consent for participation in the study.
Contact & Investigator
David S Friedman, MD, PhD, MPH
PRINCIPAL INVESTIGATOR
Massachusetts Eye and Ear
Frequently Asked Questions
Who can join the NCT06882356 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, studying Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06882356 currently recruiting?
Yes, NCT06882356 is actively recruiting participants. Contact the research team at grass@mgb.org for enrollment information.
Where is the NCT06882356 trial being conducted?
This trial is being conducted at Boston, United States, Chelsea, United States, Lynn, United States, Salem, United States and 1 additional location.
Who is sponsoring the NCT06882356 clinical trial?
NCT06882356 is sponsored by Massachusetts Eye and Ear Infirmary. The principal investigator is David S Friedman, MD, PhD, MPH at Massachusetts Eye and Ear. The trial plans to enroll 2,000 participants.